Smith Alexander Martin's Insider Trades & SAST Disclosures
Smith Alexander Martin's most recent trade in Idexx Laboratories, Inc. was a trade of 6,320 Non-Qualified Stock Option (right-to-buy) done . Disclosure was reported to the exchange on Feb. 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Smith Alexander Martin.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 6,320 | 6,320 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 1,468 | 1,468 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 593 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 593 | 1,275 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 444.53 per share. | 13 Feb 2025 | 374 | 1,391 (0%) | 0% | 444.5 | 166,254 | Common Stock |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 301 | 903 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 301 | 1,765 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 217 | 217 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 189 | 376 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 189 | 1,464 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 148 | 148 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 148 | 682 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 18 | 514 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 18 | 18 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 481.40 per share. | 01 Sep 2024 | 5 | 509 (0%) | 0% | 481.4 | 2,407 | Common Stock |
| Idexx Laboratories, Inc. | Martin Smith Alexander | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 5,407 | 5,407 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Smith Alexander Martin | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 1,204 | 1,204 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 189 | 565 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Alexander Martin Smith | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 189 | 582 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Smith Alexander Martin | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 178 | 178 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Martin Smith Alexander | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 148 | 296 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 148 | 393 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Smith Martin Alexander | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 560.56 per share. | 14 Feb 2024 | 108 | 474 (0%) | 0% | 560.6 | 60,540 | Common Stock |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 149 | 1,846 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 149 | 227 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 503.66 per share. | 14 Feb 2023 | 47 | 180 (0%) | 0% | 503.7 | 23,672 | Common Stock |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 5,316 | 5,316 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 754 | 1,995 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 201 | 201 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 19 | 49 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 19 | 1,241 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 350.00 per share. | 01 Sep 2022 | 6 | 43 (0%) | 0% | 350 | 2,100 | Common Stock |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 5,043 | 5,043 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 593 | 667 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 593 | 1,260 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Martin Alexander Smith | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 197 | 197 | - | - | Incentive Stock Option (right-to-buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges